Gadopentetate dimeglumine excretion into human breast milk during lactation

Radiology. 2000 Aug;216(2):555-8. doi: 10.1148/radiology.216.2.r00au09555.


Purpose: To analyze the amount of gadopentetate dimeglumine excreted into human breast milk following intravenous injection of a clinical dose.

Materials and methods: Gadopentetate dimeglumine was injected intravenously in 20 lactating women (23-38 years of age). Breast-feeding was interrupted for at least 24 hours. Serial samples of expressed milk were collected and analyzed for gadolinium concentration by means of inductively coupled plasma atomic emission spectrometry at a wavelength of 342.247 nm.

Results: The cumulative amount of gadolinium excreted in human breast milk during 24 hours was 0.57 micromol +/- 0.71 (SD; range, 0.05-3.0 micromol). The excreted dose was thus less than 0.04% of the administered intravenous dose (range, 0.001%-0.04%; mean, 0.009% +/- 0.010) for all cases.

Conclusion: Less than 0.04% of administered gadopentetate dimeglumine is excreted into human breast milk. The amount transferred to a nursing infant orally would be far more than 100 times less than the permitted intravenous dose (200 micromol per kilogram of body weight) for neonates. The recommendation of a 24-hour suspension of breast-feeding for lactating women should thus be reconsidered.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adult
  • Body Weight
  • Breast Feeding
  • Contrast Media / administration & dosage
  • Contrast Media / analysis
  • Contrast Media / pharmacokinetics*
  • Female
  • Follow-Up Studies
  • Gadolinium DTPA / administration & dosage
  • Gadolinium DTPA / analysis
  • Gadolinium DTPA / pharmacokinetics*
  • Humans
  • Infant, Newborn
  • Injections, Intravenous
  • Lactation*
  • Linear Models
  • Milk, Human / chemistry
  • Milk, Human / metabolism*
  • Spectrophotometry


  • Contrast Media
  • Gadolinium DTPA